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Ligation of the TNF receptor family co-stimulatory
molecule OX40 (CD134) with an agonist anti-OX40 mAb
enhances anti-tumor immunity by augmenting T cell dif-
ferentiation as well as turning off the suppressive activity
of FoxP3+CD4+ regulatory T cells (Treg). In addition,
antibody-mediated blockade of the checkpoint inhibitor,
CTLA-4, releases the “brakes” on T cells to augment
tumor immunotherapy. However, monotherapy with
these agents can have limited therapeutic benefit particu-
larly against poorly immunogenic murine tumors. There-
fore, we examined whether the combination of agonist
anti-OX40 therapy in the presence of CTLA-4 blockade
would enhance tumor immunotherapy. Combined anti-
OX40/anti-CTLA-4 immunotherapy significantly
enhanced tumor regression and the survival of tumor-
bearing hosts in a CD4 and CD8 T cell-dependent man-
ner. Mechanistic studies revealed that combination
immunotherapy directed the expansion of effector
T-bethigh/Eomeshigh granzyme B+ CD8 T cells. Dual
immunotherapy also induced among distinct populations
of Th1 (IL-2, IFN-g) and, surprisingly, Th2 (IL-4, IL-5,
and IL-13) CD4 T cells exhibiting increased T-bet and
Gata-3 expression. Furthermore, IL-4 blockade inhibited
the Th2 response, while maintaining Th1 CD4 and effec-
tor CD8 T cells that enhanced tumor-free survival. These
data demonstrate that refining the global T cell response
during combination immunotherapy can further enhance
the therapeutic efficacy of these agents.
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